Northwestern University: Glioblastoma trials

The registry lists 12 Glioblastoma studies with Northwestern University as lead sponsor. 2 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 1 6Phase 2 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent GlioblastomaRecruitingNCT06410248Phase 1
• WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaRecruitingNCT05879250Phase 2
• Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant GliomaCompletedNCT03072134Phase 1Results posted
• NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing SurgeryCompletedNCT03020017Early Phase 1Results posted
• Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant GliomaCompletedNCT02794883Phase 2Results posted
• Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent GliomasTerminatedNCT01478321Phase 2Results posted
• Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00720356Phase 2Results posted
• Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingNCT05864534Phase 2
• Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of GlioblastomaActive, not recruitingNCT05236036Phase 1
• Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent GlioblastomaActive, not recruitingNCT04528680Phase 1/2
• Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT04047706Phase 1
• Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed GlioblastomaTerminatedNCT02530502Phase 1